Nutriband (NASDAQ:NTRB) Stock Price Down 3.9% – Here’s What Happened

Posted by Max Byerly on Jul 24th, 2026

Shares of Nutriband Inc. (NASDAQ:NTRB – Get Free Report) dropped 3.9% during mid-day trading on Thursday . The stock traded as low as $2.92 and last traded at $2.93. Approximately 13,734 shares changed hands during trading, an increase of 8% from the average session volume of 12,696 shares. The stock had previously closed at $3.05.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Nutriband from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.

View Our Latest Stock Analysis on NTRB

Nutriband Stock Performance

The business has a 50 day moving average of $3.27 and a two-hundred day moving average of $3.82. The stock has a market capitalization of $35.63 million, a PE ratio of -1.14 and a beta of 1.93.

Nutriband (NASDAQ:NTRB – Get Free Report) last posted its earnings results on Thursday, June 11th. The company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $0.43 million during the quarter. Nutriband had a negative net margin of 448.25% and a negative return on equity of 112.64%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Nutriband stock. Vanguard Group Inc. lifted its position in Nutriband Inc. (NASDAQ:NTRB – Free Report) by 1.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 202,738 shares of the company’s stock after buying an additional 3,111 shares during the period. Vanguard Group Inc. owned approximately 1.68% of Nutriband worth $1,429,000 as of its most recent SEC filing. 19.70% of the stock is currently owned by hedge funds and other institutional investors.

Nutriband Company Profile

(Get Free Report)

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.